Sanfilippo Q2 Sales Rise 4.6% to $314.8M; EPS Jumps 31.9% and $1 Dividend

JBSSJBSS

John B. Sanfilippo & Son reported Q2 net sales rose 4.6% to $314.8 million with gross profit up 13.2% to $59.2 million. Diluted EPS jumped 31.9% to $1.53 as sales volume fell 9.7%, inventory rose 14.4%, and the company declared a special $1.00 per share dividend.

1. Strong Q2 Net Sales and Profit Growth

John B. Sanfilippo & Son, Inc. reported second quarter net sales of $314.8 million, a 4.6% increase year-over-year driven by a 15.8% rise in weighted average selling price per pound. Despite a 9.7% decline in sales volume to 87.0 million pounds, gross profit rose 13.2% to $59.2 million, lifting gross margin to 18.8% from 17.4% a year ago. Diluted earnings per share climbed 31.9% to $1.53, outperforming analysts’ consensus of $1.36.

2. Channel Dynamics and Volume Trends

Volume in the consumer distribution channel fell 8.4%, primarily from lower private brand bars and nuts sales due to elevated retail prices and soft demand, while branded items faced lost distribution at key non-food retailers. The commercial ingredients channel held nearly flat with a 1.1% decline, and contract manufacturing volume plunged 26.5% amid reduced granola processing at Lakeville. Core walnut, almond and pecan volumes nevertheless recorded modest gains.

3. Operational Efficiencies and Cost Management

Operating expenses remained effectively unchanged, increasing by just $0.3 million, as higher incentive compensation was offset by reductions in marketing, freight and third-party warehouse costs. As a percentage of net sales, operating expenses fell to 10.5% from 10.9% in the prior year quarter. Inventory on hand rose 14.4% to support demand forecasts, reflecting higher commodity acquisition costs and greater work-in-process levels.

4. Strategic Outlook and Capital Allocation

CEO Jeffrey T. Sanfilippo highlighted disciplined cost management, strategic pricing and tariff reductions on imported nuts as key drivers of margin improvement. The company distributed a $1.00 special dividend at the start of Q3 and initiated one of its largest capital expenditure programs to expand capacity and enhance efficiency. Management emphasized ongoing innovation in health-focused products to capture emerging market opportunities and deliver long-term shareholder value.

Sources

ZSB